Acelrx Pharmaceuticals Inc Год IPO
Что обозначает Год IPO в Acelrx Pharmaceuticals Inc?
Год IPO Acelrx Pharmaceuticals Inc является 2011
Какое определение для Год IPO?
Первичное публичное размещение акций - это тип публичного предложения, при котором акции компании обычно продаются институциональным инвесторам, которые, в свою очередь, впервые продают эти акции широкой публике на фондовой бирже.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Год IPO компаний в Health Care сектор на NASDAQ по сравнению с Acelrx Pharmaceuticals Inc
Что делает Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Компании с год ipo похож на Acelrx Pharmaceuticals Inc
- Goldman Sachs Mutual Fund - Goldman Sachs Nifty Exchange Traded Scheme имеет Год IPO из 2010
- Software Effective Solutions имеет Год IPO из 2010
- GINSMS имеет Год IPO из 2010
- Photonike Capital SA имеет Год IPO из 2010
- Parabolic Drugs имеет Год IPO из 2010
- West Kirkland Mining имеет Год IPO из 2010
- Acelrx Pharmaceuticals Inc имеет Год IPO из 2011
- Omineca Mining and Metals имеет Год IPO из 2012
- iShares Asia Trust - iShares Core CSI 300 Index ETF имеет Год IPO из 2012
- Wendy`s Co имеет Год IPO из 2012
- Unisys имеет Год IPO из 2012
- Christopher & Banks имеет Год IPO из 2012
- Wellesley имеет Год IPO из 2012